Annual Total Long Term Liabilities
$15.83 M
+$10.98 M+226.13%
31 December 2023
Summary:
SAB Biotherapeutics annual total long term liabilities is currently $15.83 million, with the most recent change of +$10.98 million (+226.13%) on 31 December 2023. During the last 3 years, it has risen by +$9.36 million (+144.71%). SABS annual total long term liabilities is now -1.90% below its all-time high of $16.14 million, reached on 31 December 2021.SABS Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$8.08 M
-$141.70 K-1.72%
30 September 2024
Summary:
SAB Biotherapeutics quarterly total long term liabilities is currently $8.08 million, with the most recent change of -$141.70 thousand (-1.72%) on 30 September 2024. Over the past year, it has increased by +$4.21 million (+108.77%). SABS quarterly long term liabilities is now -49.93% below its all-time high of $16.14 million, reached on 31 December 2021.SABS Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SABS Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +226.1% | +108.8% |
| 3 y3 years | +144.7% | -17.1% |
| 5 y5 years | - | - |
SABS Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -1.9% | +226.1% | -49.9% | +108.8% |
| 5 y | 5 years | -1.9% | +226.1% | -49.9% | +108.8% |
| alltime | all time | -1.9% | +226.1% | -49.9% | +108.8% |
SAB Biotherapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $8.08 M(-1.7%) |
| June 2024 | - | $8.22 M(-19.8%) |
| Mar 2024 | - | $10.24 M(-35.3%) |
| Dec 2023 | $15.83 M(+226.1%) | $15.83 M(+309.1%) |
| Sept 2023 | - | $3.87 M(-17.9%) |
| June 2023 | - | $4.72 M(+2.4%) |
| Mar 2023 | - | $4.60 M(-5.1%) |
| Dec 2022 | $4.85 M | $4.85 M(+1.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $4.78 M(-18.9%) |
| June 2022 | - | $5.90 M(-25.9%) |
| Mar 2022 | - | $7.96 M(-50.7%) |
| Dec 2021 | $16.14 M(+149.5%) | $16.14 M(+65.5%) |
| Sept 2021 | - | $9.75 M(+69.4%) |
| June 2021 | - | $5.76 M(-11.0%) |
| Dec 2020 | $6.47 M(-58.8%) | $6.47 M |
| Dec 2019 | $15.69 M | - |
FAQ
- What is SAB Biotherapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for SAB Biotherapeutics?
- What is SAB Biotherapeutics annual total long term liabilities year-on-year change?
- What is SAB Biotherapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for SAB Biotherapeutics?
- What is SAB Biotherapeutics quarterly long term liabilities year-on-year change?
What is SAB Biotherapeutics annual total long term liabilities?
The current annual total long term liabilities of SABS is $15.83 M
What is the all time high annual total long term liabilities for SAB Biotherapeutics?
SAB Biotherapeutics all-time high annual total long term liabilities is $16.14 M
What is SAB Biotherapeutics annual total long term liabilities year-on-year change?
Over the past year, SABS annual total long term liabilities has changed by +$10.98 M (+226.13%)
What is SAB Biotherapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of SABS is $8.08 M
What is the all time high quarterly long term liabilities for SAB Biotherapeutics?
SAB Biotherapeutics all-time high quarterly total long term liabilities is $16.14 M
What is SAB Biotherapeutics quarterly long term liabilities year-on-year change?
Over the past year, SABS quarterly total long term liabilities has changed by +$4.21 M (+108.77%)